Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
This trial will be conducted in two parts to assess the safety, tolerability and activity of a new targeted therapy. Part 1 is a dose escalation phase, and participants will receive SHR-A1811 via intravenous infusion. Part 2 is an indication expansion phase, and participants will also receive SHR-A1811 via intravenous infusion.